The ExTINGUISH Trial of Inebilizumab in NMDAR Encephalitis is a study investigating the effects of inebilizumab, a new treatment, in patients with anti-NMDAR encephalitis. This is a brain condition that can cause psychiatric issues, seizures, and other severe symptoms. The study will compare first-line treatments with either inebilizumab or a placebo. Anti-NMDAR encephalitis is confirmed by finding specific antibodies in the cerebrospinal fluid (CSF), which is the fluid around the brain and spine. Participants must be over 12 years old and meet certain health criteria. The study aims to see if inebilizumab helps improve patient outcomes by 16 weeks.
Key Points:
- The study involves 116 participants and lasts 16 weeks.
- Participants will receive either inebilizumab or a placebo, along with standard treatments.
- Participants need to attend regular visits and complete various tests.
How understandable was the trial content above?
Hard to understand
Easy to understand